ubiquitin conjugating enzyme E2 C pseudogene 1Genealiases: []
Q-omics provides the consensus-scored UBE2CP1 profile across patient tissues and cancer cell-line models. UBE2CP1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, UBE2CP1 is differentially expressed in 4, with the highest sampling consensus in PAAD. Additionally, UBE2CP1 RNA expression shows 14,189 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUSC, PAAD, and UVM as cancer lineages where UBE2CP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2CP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2CP1 survival associations across molecular data types. UBE2CP1 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2CP1 RNA expression–survival associations across cancer types. High UBE2CP1 expression shows unfavorable associations in LUSC, THCA, CESC and UVM, but favorable associations in COAD and SKCM. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for UBE2CP1 RNA expression.
This table summarizes UBE2CP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for UBE2CP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2CP1 shows lower tumor expression in BRCA and ESCA and higher tumor expression in PAAD and CHOL. The PAAD box plot shows higher UBE2CP1 RNA expression in tumor versus normal tissue (log2 FC = +0.220, t-test p = .018).
This table shows molecular features associated with UBE2CP1 in patient tissues and cancer cell lines. In patient samples, UBE2CP1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
